Division of Nestle SA
Latest From Galderma SA
Sanofi/Regeneron’s pioneering biologic, dupilumab, is growing its potential market before the advent of competing molecules. An EU approval extension, allowing use in adolescents as well as in adults, and positive Phase III results in children aged six to 11 years with severe atopic dermatitis, should help.
New OTC medicines for fungal nail infections and verrucas have been launched in the UK by Galderma, Reckitt Benckiser and Vemedia, while new foot-care products have also been introduced by Blistex, Epitact and Dermatonics.
Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.
Acne treatment study found set out to better understand the pathogenesis of pre-adolescent acne and the impact of OTC acne drug benzoyl peroxide after an earlier study showed treatment with ingredient significantly decreased alpha diversity on girls' skin.
- OTC, Consumer
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Nestle SA
- Senior Management
Humberto C Antunes, CEO
John Dickinson, VP, CFO
Gabriel Villada, VP, Mktg. & Bus. Dev.
- Contact Info
Phone: (33) 1 58 86 45 45
Avenue Gratta-Paille 2
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.